Quick Answer
Tvardi Therapeutics, Inc. reported Total Assets of $32.07 million for the year ending 2025.
- Tvardi Therapeutics, Inc. showed a decrease of -8.9% in Total Assets from 2024 to 2025.
- This data is from Tvardi Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $71.56 million | Q2 2014: $68.19 million | Q3 2014: $62.37 million | Q1 2015: $51.65 million | Q2 2015: $46.44 million | Q3 2015: $117.90 million | Q1 2016: $102.01 million | Q2 2016: $92.05 million | Q3 2016: $80.15 million | Q1 2017: $43.30 million | Q2 2017: $117.97 million | Q3 2017: $108.05 million | Q1 2018: $80.64 million | Q2 2018: $139.89 million | Q3 2018: $212.70 million | Q1 2019: $170.59 million | Q2 2019: $149.64 million | Q3 2019: $263.80 million | Q1 2020: $196.17 million | Q2 2020: $168.61 million | Q3 2020: $147.14 million | Q1 2021: $250.23 million | Q2 2021: $221.45 million | Q3 2021: $225.09 million | Q1 2022: $223.87 million | Q2 2022: $226.57 million | Q3 2022: $213.51 million | Q1 2023: $153.28 million | Q2 2023: $134.39 million | Q3 2023: $115.34 million | Q1 2024: $90.10 million | Q2 2024: $72.50 million | Q3 2024: $51.33 million | Q1 2025: $38.95 million | Q2 2025: $43.75 million | Q3 2025: $39.02 million.
- Over the full 13 years of available data (2013 to 2025), Tvardi Therapeutics, Inc.'s Total Assets has grown by 77.4%.
- Historical annual values: Fiscal year 2025: $32.07 million | Fiscal year 2024: $35.20 million | Fiscal year 2023: $125.84 million | Fiscal year 2022: $182.24 million | Fiscal year 2021: $247.06 million | Fiscal year 2020: $271.16 million | Fiscal year 2019: $232.96 million | Fiscal year 2018: $190.82 million | Fiscal year 2017: $97.00 million | Fiscal year 2016: $63.83 million | Fiscal year 2015: $110.90 million | Fiscal year 2014: $55.93 million | Fiscal year 2013: $18.08 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: